LYNPARZA® (olaparib) in Combination With Bevacizumab, and as Monotherapy, Demonstrates Clinically Meaningful Long-Term Survival in Certain Patients With First-Line Advanced Ovarian Cancer in Exploratory Analyses of Two Phase 3 TrialsBusiness Wire • 09/09/22
Goldman Sachs Says Next Fed Rate Increases Will Be Big: 7 Conviction List Dividend Stocks to Buy Now24/7 Wall Street • 09/09/22
Merck Foundation Launches $20 Million Initiative to Advance Equity in U.S. Cancer CareBusiness Wire • 09/08/22
Merck to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer PatientsBusiness Wire • 09/07/22
Merck to Present at the Morgan Stanley 20th Annual Global Healthcare ConferenceBusiness Wire • 09/06/22
8 Goldman Sachs ‘Strong Buy' Dividend Stocks That Will Generate Big and Safe Passive Income24/7 Wall Street • 09/01/22
8 Safe ‘Strong Buy' Health Care Dividend Stocks to Buy as Summer Bear Market Rally Ends24/7 Wall Street • 08/30/22
Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of CancerBusiness Wire • 08/29/22
LYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast CancerBusiness Wire • 08/25/22
Is No. 1 Pharma Stock Merck A Buy As It Reportedly Mulls A Large Takeover?Investors Business Daily • 08/24/22